Ignite Creation Date:
2025-12-26 @ 10:46 PM
Ignite Modification Date:
2026-03-02 @ 11:11 PM
Study NCT ID:
NCT00548912
Status:
WITHDRAWN
Last Update Posted:
2021-12-09
First Post:
2007-10-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease
Sponsor:
Dawnmarie DeFazio
Organization:
Study Overview
Official Title:
Cardiac Magnetic Resonance Imaging in Hemodialysis Patients
Status:
WITHDRAWN
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
study ended
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass
Detailed Description:
Dialysis patients have significant morbidity and mortality associated with left ventricular hypertrophy and cardiac failure. Aldosterone may have an important role in the development of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown significant survival benefit in a non-dialysis population with congestive heart failure. This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac hypertrophy in the end-stage renal disease population.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: